8 Biotechnology Stocks to Buy Now

Advertisement

The grades of eight biotechnology stocks are on the rise this week on Portfolio Grader. Each of these stocks is rated an “A” (“strong buy”) or “B” overall (“buy”).

Merrimack Pharmaceuticals, Inc. (MACK) is making headway this week, with the company’s rating improving to an A (“strong buy”) from a B (“buy”) last week. Merrimack Pharmaceuticals is focused on the discovery, development and commercialization of drugs for the treatment of immunological and autoimmune diseases with an initial focus on cancer. In Portfolio Grader’s specific subcategory of Sales Growth, MACK also gets an A. For more information, get Portfolio Grader’s complete analysis of MACK stock.

Genomic Health, Inc. (GHDX) is bumping up its rating from a C (“hold”) to a B (“buy”) this week. Genomic Health is a life science company, which is focused on the development and commercialization of genomic-based clinical diagnostic tests for cancer that allow physicians and patients to make individualized treatment decisions. For more information, get Portfolio Grader’s complete analysis of GHDX stock.

Mirati Therapeutics Inc. (MRTX) improves from a C to a B rating this week. Mirati Therapeutics engages in the development of therapeutics for the treatment of cancer. For more information, get Portfolio Grader’s complete analysis of MRTX stock.

Neurocrine Biosciences, Inc. (NBIX) is seeing ratings go up from a B last week to an A this week. Neurocrine Biosciences is focused on the discovery and development of therapeutics for neuropsychiatric, neuroinflammatory, and neurodegenerative diseases and disorders. For more information, get Portfolio Grader’s complete analysis of NBIX stock.

This week, MiMedx Group, Inc. (MDXG) pushes up from a C to a B rating. MiMedx Group operates as a medical device company. For more information, get Portfolio Grader’s complete analysis of MDXG stock.

Aurinia Pharmaceuticals Inc. (AUPH) gets a higher grade this week, advancing from a C last week to a B. For more information, get Portfolio Grader’s complete analysis of AUPH stock.

OPKO Health, Inc. (OPK) earns an A this week, jumping up from last week’s grade of B. OPKO Health is involved in the discovery, development, and commercialization of pharmaceutical products, vaccines, and diagnostic products. For more information, get Portfolio Grader’s complete analysis of OPK stock.

Ambit Biosciences Corp. (AMBI) shows solid improvement this week. The company’s rating rises from a C to a B. For more information, get Portfolio Grader’s complete analysis of AMBI stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.


Article printed from InvestorPlace Media, https://investorplace.com/2015/02/8-biotechnology-stocks-to-buy-now-mack-ghdx-mrtx/.

©2024 InvestorPlace Media, LLC